Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.22.2
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Segment Reporting Information [Line Items]        
Total revenues $ 38,406 $ 25,453 $ 73,746 $ 43,485
Cost of product revenue 11,270 4,318 19,791 8,536
Research and development 19,089 12,826 38,590 24,397
Selling, general and administrative 10,656 12,795 26,360 24,193
Total costs and operating expenses 41,015 29,939 84,741 57,126
Income (loss) from operations (2,609) (4,486) (10,995) (13,641)
Unallocated depreciation and amortization (1,341) (716) (2,556) (1,375)
Stock-based compensation 3,231 2,844 7,069 5,531
Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 36,530 21,585 69,629 35,815
Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 1,876 3,868 4,117 7,670
Product revenue        
Segment Reporting Information [Line Items]        
Total revenues 34,645 14,717 65,335 24,943
Product revenue | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 34,645 14,717 65,335 24,943
Product revenue | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 0 0 0 0
Research and development revenue        
Segment Reporting Information [Line Items]        
Total revenues 3,761 10,736 8,411 18,542
Research and development revenue | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 1,885 6,868 4,294 10,872
Research and development revenue | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 1,876 3,868 4,117 7,670
Operating segments        
Segment Reporting Information [Line Items]        
Total revenues 38,406 25,453 73,746 43,485
Cost of product revenue 11,270 4,318 19,791 8,536
Research and development 18,007 12,251 36,475 23,301
Selling, general and administrative 4,556 3,790 8,816 7,209
Total costs and operating expenses 33,833 20,359 65,082 39,046
Income (loss) from operations 4,573 5,094 8,664 4,439
Stock-based compensation 3,231 2,844 7,069 5,531
Operating segments | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 36,530 21,585 69,629 35,815
Cost of product revenue 11,270 4,318 19,791 8,536
Research and development 6,929 5,057 13,051 11,502
Selling, general and administrative 3,876 3,170 7,416 5,988
Total costs and operating expenses 22,075 12,545 40,258 26,026
Income (loss) from operations 14,455 9,040 29,371 9,789
Stock-based compensation 1,283 1,115 2,770 2,109
Operating segments | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 1,876 3,868 4,117 7,670
Cost of product revenue 0 0 0 0
Research and development 11,078 7,194 23,424 11,799
Selling, general and administrative 680 620 1,400 1,221
Total costs and operating expenses 11,758 7,814 24,824 13,020
Income (loss) from operations (9,882) (3,946) (20,707) (5,350)
Stock-based compensation 358 257 768 495
Operating segments | Product revenue        
Segment Reporting Information [Line Items]        
Total revenues 34,645 14,717 65,335 24,943
Operating segments | Research and development revenue        
Segment Reporting Information [Line Items]        
Total revenues 3,761 10,736 8,411 18,542
Corporate, non-segment        
Segment Reporting Information [Line Items]        
Total costs and operating expenses (5,789) (8,610) (16,994) (16,335)
Unallocated depreciation and amortization (1,316) (741) (2,549) (1,426)
Income (loss) before income taxes (2,532) (4,257) (10,879) (13,322)
Stock-based compensation $ 1,590 $ 1,472 $ 3,531 $ 2,927